drugset / Trial / NCT01430442
Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary purpose of this study is to evaluate the efficacy of rimegepant (BMS-927711) compared with placebo in the acute treatment of migraine as measured by Pain Freedom (headache pain intensity level reported as "no pain") at 2 hours post dose using a four point numeric rating scale (no pain, mild pain, moderate pain, severe pain) while identifying an optimal dose to support the Phase 3 clinical trials.
Timeline
- Start
- 2011-10
- Primary completion
- 2012-05
- Completion
- 2012-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rimegepant | Small molecule | 10 mg | Oral |
| Subject | Rimegepant | Small molecule | 25 mg | Oral |
| Subject | Rimegepant | Small molecule | 75 mg | Oral |
| Subject | Rimegepant | Small molecule | 150 mg | Oral |
| Subject | Rimegepant | Small molecule | 300 mg | Oral |
| Subject | Rimegepant | Small molecule | 600 mg | Oral |
| Comparator | Sumatriptan | Unknown | 100 mg | Oral |